Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
A Janumet pancreatic cancer lawsuit was filed after the death of a Kentucky woman whose cancer was allegedly caused by the Merck & Co. diabetes drug.
Rebecca Tite suffered from type-2 diabetes and was prescribed Janumet as a treatment, according to the wrongful death lawsuit. Janumet is the younger brother of the popular diabetic drug Januvia, following its release by a year and fueled by the good reputation Januvia had built. She and her doctor believed Janumet to be safe, and did not realize it could cause pancreatic cancer, according to the Janumet side effects lawsuit. Tite starting taking Janumet in 2010 and was diagnosed with pancreatic cancer in 2011. She died in 2012.
The Janumet cancer lawsuit alleges that information about the connection between the drug and pancreatic cancer was withheld from Tite and, therefore, she could not have made an informed decision to take the drug. It was Merck’s responsibility to warn all patients about the potential side effects for each of its products, the Janumet lawsuit said. The Janumet lawsuit accuses Merck & Co. of negligence, false advertising, concealing information, and misrepresenting a product.
The Janumet Cancer Lawsuit is In Re: Incretin-Based Therapies Product Liability Litigation, MDL No. 2452, in the U.S. District for the Southern District California.
Overview of Janumet
Janumet was approved in 2007, following the success of Januvia, also manufactured by Merck & Co. Both patients and medical experts favor these medications for their efficiency, and were encouraged to try the drugs by Merck’s Janumet and Januvia marketing campaigns. Janumet is a part of a recently approved class of therapeutic drugs that is specifically designed to treat type-2 diabetes, called dipeptidyl peptidase-4 (DPP-4) inhibitors. The drugs signal incretins in the body to produce more insulin, which prevents diabetic attacks.
Although numerous users have allegedly developed pancreatic cancer after taking Januvia or Janumet, neither mentions the risk on its label. That has fueled numerous Januvia and Janumet cancer lawsuits.
In general, type-2 diabetes treatment drug lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or class action lawsuit is best for you. Hurry — statutes of limitations may apply.
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Get Help – It’s Free
Join a Free Januvia, Janumet, Byetta, Victoza Cancer Class Action Lawsuit Investigation
If you or your loved one took Januvia, Victoza, Janumet or Byetta and were diagnosed with pancreatic cancer or thyroid cancer, you have a legal claim. See if you qualify by filling out the short form below.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
Oops! We could not locate your form.
